The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: A large prospective cohort study in China. Issue 48 (4th December 2017)
- Record Type:
- Journal Article
- Title:
- The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: A large prospective cohort study in China. Issue 48 (4th December 2017)
- Main Title:
- The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: A large prospective cohort study in China
- Authors:
- Lu, Ying
Zhu, Feng-Cai
Liu, Jian-Xun
Zhai, Xiang-Jun
Chang, Zhan-Jun
Yan, Ling
Wei, Kai-Ping
Zhang, Xin
Zhuang, Hui
Li, Jie - Abstract:
- Abstract: Background: Antiviral therapy has been documented to reduce perinatal transmission of hepatitis B virus (HBV) in highly viremic mothers. This large prospective cohort study conducted in China aims to delineate the maternal viral threshold for consideration of antiviral prophylaxis in settings with limited resources. Methods: A total of 1177 mother-infant pairs with positive maternal hepatitis B surface antigen (HBsAg) under current passive-active prophylaxis regimen were enrolled from community health centers in Jiangsu and Henan provinces, China. Maternal hepatitis B e antigen (HBeAg) status and viral load were tested at 36–40 weeks of gestation. Post-vaccination serologic testing was performed at 7 and 12 months of age. Results: HBeAg-positive mothers (419/1177; 35.6%) had significantly higher viral loads, compared with HBeAg-negative mothers (758/1177; 64.4%) (8.12 vs. 2.69 log IU/mL, p < .0001). Twenty infants, born to HBeAg-positive mothers with high viral loads (median, 8.38; range: 7.82–9.22 log IU/mL), were infected at 7 months of age. In contrast, none of the HBeAg-negative mothers transmitted HBV to their offspring. After adjustment for the other risk factor, a higher maternal viral load was significantly associated with a higher risk of transmission (adjusted odds ratio, 3.78; 95% confidence interval: 1.46–9.81; p = .006). The rates of passive-active immunoprophylaxis failure were 0.0% (0/789), 0.0% (0/27), 0.0% (0/32) and 6.1% (20/329) at maternalAbstract: Background: Antiviral therapy has been documented to reduce perinatal transmission of hepatitis B virus (HBV) in highly viremic mothers. This large prospective cohort study conducted in China aims to delineate the maternal viral threshold for consideration of antiviral prophylaxis in settings with limited resources. Methods: A total of 1177 mother-infant pairs with positive maternal hepatitis B surface antigen (HBsAg) under current passive-active prophylaxis regimen were enrolled from community health centers in Jiangsu and Henan provinces, China. Maternal hepatitis B e antigen (HBeAg) status and viral load were tested at 36–40 weeks of gestation. Post-vaccination serologic testing was performed at 7 and 12 months of age. Results: HBeAg-positive mothers (419/1177; 35.6%) had significantly higher viral loads, compared with HBeAg-negative mothers (758/1177; 64.4%) (8.12 vs. 2.69 log IU/mL, p < .0001). Twenty infants, born to HBeAg-positive mothers with high viral loads (median, 8.38; range: 7.82–9.22 log IU/mL), were infected at 7 months of age. In contrast, none of the HBeAg-negative mothers transmitted HBV to their offspring. After adjustment for the other risk factor, a higher maternal viral load was significantly associated with a higher risk of transmission (adjusted odds ratio, 3.78; 95% confidence interval: 1.46–9.81; p = .006). The rates of passive-active immunoprophylaxis failure were 0.0% (0/789), 0.0% (0/27), 0.0% (0/32) and 6.1% (20/329) at maternal viral loads of <5, 5–6, 6–7 and ≥7 log IU/mL, respectively. The antibody to hepatitis B surface antigen (anti-HBs) response rate was 98.4% (1138/1157) at 7 months of age. Conclusions: Results from this study indicate that the maternal viral threshold associated with perinatal transmission of HBV is 7 log IU/mL, which may be appropriate for consideration of antiviral prophylaxis in settings with limited resources. … (more)
- Is Part Of:
- Vaccine. Volume 35:Issue 48(2017)Part B
- Journal:
- Vaccine
- Issue:
- Volume 35:Issue 48(2017)Part B
- Issue Display:
- Volume 35, Issue 48, Part 2 (2017)
- Year:
- 2017
- Volume:
- 35
- Issue:
- 48
- Part:
- 2
- Issue Sort Value:
- 2017-0035-0048-0002
- Page Start:
- 6627
- Page End:
- 6633
- Publication Date:
- 2017-12-04
- Subjects:
- HBV hepatitis B virus -- MTCT mother-to-child transmission -- HBsAg hepatitis B surface antigen -- HBeAg hepatitis B e antigen -- HBIG hepatitis B immunoglobulin -- EASL European Association for the Study of Liver -- AASLD American Association for the Study of Liver Diseases -- ALT alanine aminotransferase -- PVST post-vaccination serologic testing -- CMIA chemiluminescent microparticle immunoassay -- nPCR nested polymerase chain reaction -- anti-HBs antibody to hepatitis B surface antigen -- CI confidence interval -- GMC geometric mean concentration -- OR odds ratio -- HLA human leukocyte antigen -- MHR major hydrophilic region -- WHO world health organization -- CDC Centers for Disease Control and Prevention
Hepatitis B virus -- Hepatitis B virus DNA -- Vaccination -- Mother-to-child transmission -- Immunoprophylaxis failure -- Viral threshold
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0264410X ↗
http://www.clinicalkey.com/dura/browse/journalIssue/0264410X ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0264410X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.vaccine.2017.10.032 ↗
- Languages:
- English
- ISSNs:
- 0264-410X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9138.628000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 5435.xml